IronMagLabs


AAEFX cited by FDA for cGMP violations

Results 1 to 3 of 3
  1. #1
    Senior Member
    ADMINISTRATOR
    Prince's Avatar


    Join Date
    Nov 2000
    Gender
    Male
    Location
    Panama
    Posts
    63,141
    Rep Points
    2147483647

    Post AAEFX cited by FDA for cGMP violations






    AAEFX cited by FDA for cGMP violations
    by Anthony Roberts

    AAEFX, otherwise known as All American Pharmaceuticals, has been cited for numerous violations by the FDA, based on an inspection of their facilities occuring August 5-6 of 2010. The letters were addressed to company owner Jeff Golini, who has appeared in ads for the company, calling himself “The Freak Maker.”

    Golini and AAEFX were also sent an FDA letter back in 2004 for violating numerous regulations, regarding…well everything, from lying on their site, to selling prohormones, to making drug like claims, and everything in between.

    You may recall advertisements with their company’s owner, Jeffrey M. Gollini, who is pictured wearing hospital scrubs, with the

    I’ve never been impressed by this company, and think the majority of their products are fairly awful. As for their creatine, which seems to be the flagship product, it’s 1/3rd hype, 1/3rd bad science, and 1/3rd creatine – and it’s the best product in their line.

    Anyway, the FDA cited them for not having adequate records for various formulas, no records for sanitation of machinery, inadequate documentation for required procedures, facilities that weren’t properly set up, and highly questionable protocol for in-house labeling and weighing.

    Here’s a copy of the 2011 letter, followed by the one they received in 2004:

    WARNING LETTER - January 14 2011

    Dear Mr. Gollini:

    On August 5 and 6, 2010, the U.S. Food and Drug Administration (FDA) inspected your firm located at 2376 Main Street, Billings, Montana. Our investigators found a number of serious violations of the Current Good Manufacturing Practice (CGMP) regulations in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations (CFR), Part 111. At the conclusion of the inspection, you were issued a Form FDA 483, List of Inspectional Observations, which delineated a number of violations that cause your dietary supplement products to be adulterated within the meaning of Section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. ยง 342(g)(1)) in that the dietary supplements have been prepared, packed, or held under conditions that do not meet current good manufacturing practice regulations for dietary supplements. You may find the Act and FDA regulations through links at FDA’s home page at http://www.fda.gov1.

    The following violations were observed during the inspection:

    1. You failed to prepare and follow a written master manufacturing record for each unique formulation of a dietary supplement that you manufacture, and for each batch size, as required by 21 CFR 111.205(a). You presented our investigators with a bill of materials for one unit of one of your firm’s dietary supplements as an example of your master manufacturing records. However, the bills of materials neither identify specifications for the manufacturing process, nor establish controls and procedures to ensure that the specifications are met, as required by 21 CFR 111.205(b). In addition, the master manufacturing record for each supplement and batch size must include the required elements listed in 21 CFR 111.210.

    Your firm’s August 13, 2010, response is inadequate because it fails to provide documentation of the master manufacturing records of any of your firm’s supplements. We will verify the adequacy of each master manufacturing record during our next inspection.

    2. You failed to include in your batch production record (BPR), the following mandatory elements, as required by 21 CFR 111.260:

    • Your BPR failed to include, when required, reconciliation of any discrepancies between issuance and use of labels, as required by 21 CFR 111.260(k)(1). Specifically, the BPR for packaging AAEFX ZMA 90 capsules, batch ticket # 9753, does not provide any space for reconciliation and no reconciliation is documented. This dietary supplement requires such reconciliation because examination for correct labels is not performed by electronic or electromechanical equipment (see 21 CFR 111.410(b)).

    Your response states that label reconciliation is documented and recorded on your batch records and you provide the example of batch ticket #9753, which indicates (b)(4) labels used; however, there is no information recorded about the number of labels issued on the batch ticket. The nonconformance report that you indicate was added to explain discrepancies between the number of labels used and the number of completed bottles does not address discrepancies between the issuance and use of labels. Your response also states that you have added a label reconciliation procedure; however, it does not address the missing information required to be on your batch records nor does it include written instructions for reconciliation.

    • Your BPR failed to include the date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained, as required by 21 CFR 111.260(c). Our inspection found that your BPR did not include this information.

    • Your BPR failed to include the identity of equipment and processing lines used in producing the batch, as required by 21 CFR 111.260(b). Specifically, our investigation found that batch records did not include this information. Batch ticket # 8445 failed to identify the blender used on the blend portion or any other portion of the ticket. Batch ticket # 8444, for the capsule filling (manufacturing) portion of the batch does not identify which of the (b)(4) capsule presses was used to produce the filled capsules.

    Your response states that you have added the equipment and processing lines used to your BPR, and you provided batch ticket #9379 as an example. We will verify that your BPR includes all mandatory elements during our next inspection.

    3. You failed to control the issuance and use of packaging and labels, as required by 21 CFR 111.410(b). Specifically, our investigation found that your lot code setting, start up, misalignment and otherwise damaged labels were not kept to be reconciled at the end of the labeling operation, and you employ no control measures to verify that only the correct labels are used in labeling your products. Furthermore, our investigators observed that the quantity of roll stock pressure sensitive labels returned to the label room was inaccurate because the number of labels issued only reflected the number required in the batch ticket.

    This letter is not an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment and the products you market comply with the Act and its implementing regulations.

    Failure to promptly correct the violations specified above may result in enforcement action without further notice. Enforcement action may include seizure of violative products and/or injunction.

    Additional Comments

    We note that our investigator observed several instances in which your firm failed to take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements including segregating and identifying all containers for a specific batch of dietary supplements to identify their contents and, when necessary, the phase of manufacturing. Our investigator observed:

    a) Drums bearing no positive identification or marked with multiple identifications. For example, our investigators observed a drum in the blending room identified with an in-house QC sticker marked as Arginine AKG and “Cleared for Production” was also identified with a printed label identifying the product as Calcium (b)(4).

    b) Raw materials in the weigh room that had not been weighed were not segregated from weighed batches ready to move from the weigh room into the blending room, nor were there controls to positively identify each weighed batch. For example, a pallet of fiber drums with three components, identified as Prota-Lynn Whey Hybrid, Karbo-Lyn, and Kre-Alkalyn, used by your firm to add partial quantities to batches containing the components, was placed directly behind a weighed and staged pallet of components in the weigh room identified by the blending batch ticket # 9457. There was no separation and no marking to distinguish the pallet containing the unweighed Prota-Lynn Whey Hybrid, Karbo-Lyn, and Kre-Alkalyn from the weighed components of batch # 9457.

    c) An unmarked bottle at the foot of a filling machine being used to fill bottles with the dietary supplement identified as Kre-Alklyn 120 that contained capsules of a different color and size from those being filled. The bottle was identified as being from a previous batch production.

    Within 15 working days from your receipt of this letter, please notify this office in writing of the specific steps you have taken to correct the violations noted above and to ensure that similar violations do not occur. Your response should include any documentation necessary to show that correction has been achieved. If you cannot complete all corrections before you respond, state the reason for the delay and the date by which you will have completed the corrections.

    Your written reply should be sent to the following address: U.S. Food and Drug Administration, Attention: Heidi Marks, Compliance Officer, 22201 23rd Drive SE, Bothell, WA 98021-4421. If you have any questions regarding any issue in this letter, please contact Heidi Marks at (425) 483-4862 or via email at heidi.marks@fda.hhs.gov.

    Sincerely,
    Charles M. Breen
    District Director
    http://www.anthonyroberts.info/2011/...mp-violations/





    IronMagLabs 15% Discount Code: Robert15



    IronMag Research 15% Discount Code: Robert15



  2. #2
    Senior Member
    BOARD REP
    irish_2003's Avatar


    Join Date
    Jul 2010
    Gender
    Male
    Location
    on the boards
    Posts
    5,439
    Rep Points
    326974655

    i don't really know how i feel about the FDA lately.....on one hand their helping clean up the supplement industry, but on the other hand it could potentially be harder to produce great supplements/ph's/ps's, etc......
    www.euroking-gear.net
    please know and follow the laws of your country regarding aas

  3. #3
    Senior Member
    ADMINISTRATOR
    Prince's Avatar


    Join Date
    Nov 2000
    Gender
    Male
    Location
    Panama
    Posts
    63,141
    Rep Points
    2147483647






    The FDA is a joke, if you think they're trying to protect us than why is tobacco legal? How about all of the prescription drugs that hit the market as "FDA approved" and side effects such as DEATH are possible!





    IronMagLabs 15% Discount Code: Robert15



    IronMag Research 15% Discount Code: Robert15



Similar Threads

  1. Replies: 0
    Last Post: 06-21-2011, 06:17 PM
  2. Hoopies P/RR/S AND AAEFX LOG
    By HOOPIE in forum Online Journals
    Replies: 199
    Last Post: 02-07-2010, 03:31 PM
  3. My Trip to Montana and AAEFX HQ!
    By gopro in forum Supplements
    Replies: 3
    Last Post: 05-13-2009, 10:55 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
DISABLED END -->